Nasus Medical

Nasus Medical is a private medical device and drug-delivery company developing a patient-administered intranasal delivery platform intended to improve deposition of therapies into deeper target nasal anatomy. The company is initially focused on chronic rhinosinusitis, where it aims to offer a less invasive, at-home alternative to oral steroids, office-based injections, and surgery. Its technology combines an intranasal delivery approach with a proprietary device designed to overcome the limitations of standard nasal sprays. Nasus originated from the Stanford Biodesign program and has been associated with Fogarty Innovation and StartX Med. The platform may also have broader applications in CNS, systemic, and vaccine delivery, but the lead development emphasis appears to remain chronic sinusitis.